Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.

Molecular therapy : the journal of the American Society of Gene Therapy - 2 Aug 2017

Xu Lei, Yang Huan, Gao Yang, Chen Zeyu, Xie Liangfu, Liu Yulin, Liu Ying, Wang Xiaobao, Li Hanwei, Lai Weifeng, He Yuan, Yao Anzhi, Ma Liying, Shao Yiming, Zhang Bin, Wang Chengyan, Chen Hu, Deng Hongkui

Abstract excerpt

Transplantation of hematopoietic stem cells (HSCs) with a naturally occurring CCR5 mutation confers a loss of detectable HIV-1 in the patient, making ablation of the CCR5 gene in HSCs an ideal therapy for an HIV-1 cure. Although CCR5 disruption has been attempted in CD4+ T cells and hematopoietic stem/progenitor cells (HSPCs), efficient gene editing with high specificity and long-term therapeutic potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Colony-Forming Units Assay

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Frameshift Mutation

Share to Gene Editing

Share to Gene Targeting

Share to Hematopoietic Stem Cells

Share to Receptors, CCR5

Share to RNA, Guide, CRISPR-Cas Systems

Source

Open in PubMed Open full text

Identifiers

PMID: 28527722
DOI: 10.1016/j.ymthe.2017.04.027
PMCID: PMC5542791

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.PMID 28527722Read ↗

CRISPR/Cas9-mediated gene disruption of endogenous co-receptors confers broad resistance to HIV-1 in human primary cells and humanized miceSemantic proximity Read ↗

High frequency CCR5 editing in human hematopoietic stem progenitor cells protects xenograft mice from HIV infectionSemantic proximity Read ↗

Optimizing CRISPR/Cas9 genome editing in primary human hematopoietic cells to advance studies into HIV biologySemantic proximity Read ↗

Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids.Semantic proximity Read ↗

Biallelic, Selectable, Knock-in Targeting of CCR5 via CRISPR-Cas9 Mediated Homology Directed Repair Inhibits HIV-1 Replication.Semantic proximity Read ↗

The clinical applications of genome editing in HIVSemantic proximity Read ↗

Combining Cell-Intrinsic and -Extrinsic Resistance to HIV-1 By Engineering Hematopoietic Stem Cells for CCR5 Knockout and B Cell Secretion of Therapeutic AntibodiesSemantic proximity Read ↗

Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates.Semantic proximity Read ↗

Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV‐1 InfectionSemantic proximity Read ↗

CCR5-edited gene therapies for HIV cure: Closing the door to viral entry.Semantic proximity Read ↗

Clinical hematopoietic stem cell-based gene therapySemantic proximity Read ↗

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.